Navigation Links
A novel treatment may reduce myocardial infarction size
Date:2/27/2014

Researchers at the University of Eastern Finland (UEF) have developed a novel treatment for myocardial infarction. In a study carried out at the UEF, virus vectors were used in a mouse model to deliver small RNA molecules into the heart, and this significantly reduced the size of myocardial infarction. In the novel treatment method, RNA molecules are targeted at the regulatory area of the vascular endothelial growth factor gene (VEGF-A). These molecules use epigenetic mechanisms to enhance the production of the growth factor in cells.

The study also focused on the mechanisms of this new treatment, epigenetherapy, in cell models. The study was carried out in collaboration between researchers of the MRI Research Group at the A.I. Virtanen Institute for Molecular Sciences at the UEF, the University of Jyvskyl, and Temple University in Philadelphia. The study was published in PLOS ONE on 26 February.


'/>"/>
Contact: Seppo Ylä-Herttuala
seppo.ylaherttuala@uef.fi
358-403-552-075
University of Eastern Finland
Source:Eurekalert

Page: 1

Related medicine news :

1. A new target for cancer and diabetes: A novel role for the adaptor protein p66shc in regulating glucose metabolism
2. Novel compound keeps Parkinsons symptoms at bay in mice
3. New company to develop novel gene therapies
4. Novel technique increases detection rate in screening mammography
5. Researchers find novel approach for controlling deadly C. difficile infections
6. Novel genes determine division of labor in insect societies
7. Novel biomarker approach suggests new avenues to improve schizophrenia disease management
8. Development of a novel dual JAK/Src kinase inhibitor
9. Jesus Was Not Born On December 25th - Controversial New Novel Tells Compelling Story About His Birth, Life and Death
10. Fatigue, a common side effect of breast cancer treatment, evaluated in novel patient study
11. Novel drug regimen can improve stem cell transplantation outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... City ... holidays (IBT World Travel Trends Report). As travelers visit both urban destinations, they ... temperatures, and prolonged sun exposure. In response, the outdoor industry has blurred the ...
(Date:3/28/2017)... ... , ... Alert Sentry Group LLC., a leader in the Personal Emergency Response ... and the iSAFE Plus. These iSAFE products are the most affordable and most advanced ... iSAFE Plus offer direct GPS Location and two-way calling with the push of a ...
(Date:3/28/2017)... ... 2017 , ... The Radiology Business Management Association (RBMA) is pleased ... new executive director. Mr. Still was selected through a careful months-long search by the ... is known to our members, has been a part of building the RBMA since ...
(Date:3/28/2017)... Vilnius, Lithuania (PRWEB) , ... March 28, 2017 ... ... identification technologies, today announced the release of two biometric time and attendance tracking ... Bio Attendance 4.0 software. NCheck Cloud Bio Attendance uses biometric face recognition ...
(Date:3/28/2017)... ... 28, 2017 , ... The Executives, Staff & Clients of MGE: Management Experts ... for Tots Literacy Campaign at their Semi-Annual Graduation and Fundraiser Event at MGE’s St. ... ranks at number 14 internationally in literacy. Statistically, a direct relation can be a ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... TORONTO , March 28, 2017 /PRNewswire/ ... full service medical device development firm, announced today that ... Toronto -based medical device industrial design and ... medtech companies throughout North America ... medical device talent spanning the design, engineering, regulatory, and ...
(Date:3/28/2017)... , March 28, 2017 Emosis SAS, ... new business entity, Emosis Ltd, headquartered in Tel Aviv ... novel assays complementing the mother company existing technology platform and test ... sales development of Emosis kits. ... This strategic move starts building Emosis international footprint. Emosis ...
(Date:3/28/2017)... 2017 RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... Patent Office (JPO) for the composition of matter ... for the treatment or prevention of fibrotic disorders, ... proliferative retinopathy (Japanese Patent #: 6060071).  This patent ...
Breaking Medicine Technology: